Sun Pharma buys Ranbaxy in $3.2bn all-share deal

Deal will turn Sun Pharma into the world's fifth-largest generic drug company but some analysts doubt it can turn Ranbaxy around.

Sun Pharmaceutical has agreed to buy Ranbaxy Laboratories in an all-stock deal that values the rival Indian company at $3.2 billion, potentially creating the world's fifth-largest generic drug maker.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media